Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Fig. 1

Significant down-regulation of hsa-miR-181a-5p and RNU6-2 as shown by arrows when Group 1 (CML patients responsive to imatinib therapy); was compared with the Control Group (blood donors) using custom array plate and real-time RT-qPCR. The custom array plate consisted of 18 miRNAs selected from NGS. RNU6-2 is a reference gene

Back to article page